Sugi Predict

Sugi Predict / Compounds / SCHEMBL725346

SCHEMBL725346

SCHEMBL725346

Cc1cccnc1-c1cccc(C(=O)OC(C)(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 9/20 0.46
▸ CYP2A6 P11509 1/20 0.43
▸ ABCG2 Q9UNQ0 2/20 0.43
▸ ABCB1 P08183 1/20 0.43
▸ SLC7A5 Q01650 1/20 0.41
▸ SCN5A Q14524 1/20 0.39
▸ SCN9A Q15858 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ PDK1 Q15118 1/20 0.39
▸ PDK2 Q15119 1/20 0.39
▸ PDK3 Q15120 1/20 0.39
▸ PDK4 Q16654 1/20 0.39
▸ ABL1 P00519 1/20 0.38
▸ GRM1 Q13255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27806372 0.88 ALDH1A1 (0.50) TRPV1CYP2A6SCN5ASCN9AALDH1A1
SCHEMBL28231635 0.86 SCN5A (0.47) TRPV1ABCG2ABCB1SLC7A5SCN5A
SCHEMBL28655212 0.85 TRPV1 (0.56) TRPV1CYP2A6ABCG2ABL1
SCHEMBL15151310 0.84 CYP2A6 (0.45) TRPV1CYP2A6SCN5ASCN9AALDH1A1
SCHEMBL16237821 0.83 TP53 (0.49) ALDH1A1HPGD
SCHEMBL2392623 0.80 KMO (0.54) TRPV1CYP2A6
SCHEMBL12267358 0.80 CYP2A6 (0.50) TRPV1CYP2A6ABL1
SCHEMBL19439096 0.80 ABCG2 (0.41) ABCG2ABCB1SLC7A5
SCHEMBL725997 0.80 SLC7A5 (0.43) ABCG2ABCB1SLC7A5
SCHEMBL18425126 0.80 ABCG2 (0.41) TRPV1ABCG2ABCB1SLC7A5L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108506-A1 METHODS OF TREATMENT FOR CYSTIC FIBROSIS VERTEX PHARMACEUTICALS INCORPORATED 2026-04-23 — — US disclosed
US-20260092047-A1 MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR VERTEX PHARMA (US) 2026-04-02 — — US disclosed
EP-4218754-B1 VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS VERTEX PHARMA (US) 2026-03-25 — — EP disclosed
US-12508231-B2 Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-30 — — US disclosed
US-12384762-B2 Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-08-12 — — US disclosed
US-12350262-B2 Methods of treatment for cystic fibrosis VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-07-08 — — US disclosed
EP-3880197-B9 METHODS OF TREATMENT FOR CYSTIC FIBROSIS VERTEX PHARMA (US) 2025-07-02 — — EP disclosed
EP-4556008-A2 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES Vertex Pharmaceuticals Incorporated (US) 2025-05-21 — — EP disclosed
EP-3470063-B1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES VERTEX PHARMA (US) 2025-01-01 — — EP disclosed
US-20240368189-A1 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators VERTEX PHARMA (US) 2024-11-07 — — US disclosed
WO-2010037066-A2 DOSAGE UNITS OF 3-(6-(1-(2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-01 — — WO disclosed
US-20100036130-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-02-11 — — US disclosed
US-20090176989-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS VERTEX PHARMACEUTICALS INCORPORATED 2009-07-09 — — US disclosed
US-20090176839-A1 FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID VERTEX PHARMACEUTICALS INCORPORATED 2009-07-09 — — US disclosed
US-20090170905-A1 SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID VERTEX PHARMACEUTICALS INCORPORATED 2009-07-02 — — US disclosed
WO-2009076141-A2 FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCKLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-18 — — WO disclosed
WO-2009073757-A1 SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3] DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-11 — — WO disclosed
US-20080286204-A1 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED 2008-11-20 — — US disclosed
US-20080286204-A1 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED 2008-11-20 — — US disclosed
US-20080286204-A1 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED 2008-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12350262-B2 Methods of treatment for cystic fibrosis CFTR, SLC26A4, SCNN1B TRPV1 2344/4885CYP2A6 3156/4885ABCG2 566/4885
US-20090176989-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS DDC, PCCA, KMO TRPV1 1667/4885CYP2A6 76/4885ABCG2 3036/4885
US-20260108506-A1 METHODS OF TREATMENT FOR CYSTIC FIBROSIS CFTR, CLCN2, SCNN1B TRPV1 329/4885CYP2A6 1550/4885ABCG2 244/4885
US-12384762-B2 Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator CFTR, SLC26A4, TMEM109 TRPV1 46/4885CYP2A6 1065/4885ABCG2 68/4885
US-20080286204-A1 MODULATORS OF CFTR CFTR, ABCB1, ABCC4 TRPV1 149/4885CYP2A6 1386/4885ABCG2 19/4885
US-20240368189-A1 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators CFTR, SLC26A4, ABCB11 TRPV1 143/4885CYP2A6 988/4885ABCG2 104/4885
US-20260092047-A1 MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR CFTR, SLC26A3, SLC26A4 TRPV1 128/4885CYP2A6 795/4885ABCG2 178/4885
US-20100036130-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS DDC, PCCA, KMO TRPV1 1667/4885CYP2A6 76/4885ABCG2 3036/4885
US-20090170905-A1 SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CALU, CA5B TRPV1 2629/4885CYP2A6 21/4885ABCG2 50/4885
US-20090176839-A1 FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID DDC, P2RX6, CTSC TRPV1 1197/4885CYP2A6 107/4885ABCG2 276/4885
US-12508231-B2 Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid CFTR, MFAP1, CMA1 TRPV1 645/4885CYP2A6 1270/4885ABCG2 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.